Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects

NCT05102552 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteer

Interventions

DRUG: SPN-817, Treatment B
DRUG: SPN-817, Treatment C
DRUG: BIS-001, Treatment A

Sponsor

Supernus Pharmaceuticals, Inc.